GV 2019, L.P. 13D and 13G filings for Prime Medicine, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-11-12 4:30 pm Purchase | 2025-09-30 | 13G | Prime Medicine, Inc. PRME | GV 2019, L.P. | 16,562,498 12.300% | 1,500,000 (+9.96%) | Filing |
| 2024-02-29 4:15 pm Purchase | 2024-02-20 | 13G | Prime Medicine, Inc. PRME | GV 2019, L.P. | 15,062,498 12.200% | 3,200,000 (+26.98%) | Filing |
| 2024-02-09 4:09 pm Sale | 2023-12-31 | 13G | Prime Medicine, Inc. PRME | GV 2019, L.P. | 11,862,498 12.200% | -1,422,190 (-10.71%) | Filing |
| 2023-02-10 4:05 pm Purchase | 2022-12-31 | 13G | Prime Medicine, Inc. PRME | GV 2019, L.P. | 13,284,688 13.700% | 13,284,688 (New Position) | Filing |